Global Selective Estrogen Receptor Degraders (SERD) Therapeutics Market, By Type (Faslodex, GDC-9545, RAD1901, SAR439859, AZD9833, Others), Application (First-line Treatment, Second-line Treatment), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.
Market Analysis and Insights: Global Selective Estrogen Receptor Degraders (SERD) Therapeutics Market
Selective estrogen receptor degraders (SERD) therapeutics market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 16.66% in the above mentioned forecast period.
Selective estrogen receptor degraders (SERD) are the drugs that inhibit the estrogen receptor alpha or block the production of estrogen. They are effective in the treatment of metastatic breast cancer. Fulvestrant is the first and only SERD that has been clinically approved for the treatment of breast cancer.
Rising incidence of breast cancer, unmet clinical benefits with the existing treatment of breast cancer targeting hormone receptor-positive metastatic breast cancer, growing healthcare expenditure, use of oral drug delivery as advanced route of administration, limited dosage exposure, growing government and private funding for improved safety and outcomes provided by SERD therapy are the factors that will expand the selective estrogen receptor degraders (SERD) therapeutics market.
Rising focus of key players on the research and development activities for new product launch and increasing use of SERDs as combination therapy will provide beneficial opportunities for the selective estrogen receptor degraders (SERD) therapeutics market in the forecast period of 2021-2028.
However, resistance to endocrine therapy and high cost associated with the therapy are the factors that will hinder the market growth and will further challenge the SERD therapeutics market in the forecast period mentioned above.
This selective estrogen receptor degraders (SERD) therapeutics market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the selective estrogen receptor degraders (SERD) therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Selective Estrogen Receptor Degraders (SERD) Therapeutics Market Scope and Market Size
The selective estrogen receptor degraders (SERD) therapeutics market is segmented on the basis of type, application, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of type, the selective estrogen receptor degraders (SERD) therapeutics market is segmented into faslodex, GDC-9545, RAD1901, SAR439859, AZD9833 and others.
- On the basis of application, the selective estrogen receptor degraders (SERD) therapeutics market is segmented into first-line treatment and second-line treatment.
- On the basis of end-users, the selective estrogen receptor degraders (SERD) therapeutics market is segmented into clinic, hospital and others.
The selective estrogen receptor degraders (SERD) therapeutics market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Selective Estrogen Receptor Degraders (SERD) Therapeutics Market Country Level Analysis
Selective estrogen receptor degraders (SERD) therapeutics market is analyzed and market size information is provided by the country, type, application, end-users and distribution channel as referenced above.
The countries covered in the selective estrogen receptor degraders (SERD) therapeutics market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the selective estrogen receptor degraders (SERD) therapeutics market due to the presence of major key players, growing incidence of breast cancer, relapse from existing endocrine therapies, high healthcare expenditure and well-developed healthcare sector in this region. Asia-Pacific is expected to grow during the forecast period of 2021-2028 due to the increasing research and development activities, rising investment in the healthcare sector and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Selective estrogen receptor degraders (SERD) therapeutics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Selective Estrogen Receptor Degraders (SERD) Therapeutics Market Share Analysis
Selective estrogen receptor degraders (SERD) therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to selective estrogen receptor degraders (SERD) therapeutics market research.
The major players covered in the selective estrogen receptor degraders (SERD) therapeutics market report are AstraZeneca, Lilly, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Sanofi, Novartis AG, Sandoz International GmbH, Mylan N.V., Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Limited, Accord Healthcare, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, G1 Therapeutics, Inc., HBT Labs, Radius Health, Inc., Zenopharm, ZENTALIS PHARMACEUTICALS, among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-
